Announcements
Sidley Represents BioRender in Investment Valuing Company at $900 Million
January 2, 2026
Sidley represented BioRender, a scientific communication platform with the mission of accelerating the world’s ability to learn, discover, and communicate science, in connection with a strategic investment from Dimension Capital that values the company at approximately $900 million. As part of the transaction, BioRender provided liquidity to its employees.
The Sidley team was led by Michael Podolny (Emerging Companies and Venture Capital), and included Chloe Kaufman and Celine Gruaz (Emerging Companies and Venture Capital); Nicholas Frey (Employee Benefits and Executive Compensation); and Jonathan Westreich (Tax).
連絡先
得意分野
Suggested News & Insights
Sidley Represents Cymphony in Its US$30 Million Series A FinancingSeptember 18, 2026When the Meeting Minutes and the AI Transcript Don’t Match: Litigation Insights From Delaware ChancerySeptember 17, 2026Sidley Represents Noetive in US$41 Million Series Seed FinancingSeptember 17, 2026Sidley Represents Verily Health in Investment from NVIDIASeptember 11, 2026The Evolving Regulatory Landscape for Private Credit: Key Considerations for LendersSeptember 3, 2026Sidley Represents Werewolf Therapeutics in Merger with Ambros Therapeutics and Concurrent US$150 Million Private PlacementAugust 21, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory


